Moleculin to Report Full Year 2024 Financial Results on March 21, 2025 and Host Conference Call and Webcast
Moleculin Biotech (Nasdaq: MBRX), a late-stage pharmaceutical company focused on developing treatments for hard-to-treat tumors and viruses, has scheduled its full year 2024 financial results announcement for March 21, 2025.
The company will host a conference call and live audio webcast to discuss operational and financial results on March 24, 2025, at 8:30 AM ET. Investors can join via phone by dialing (877) 407-0832 (domestic) or (201) 689-8433 (international). The webcast will be available on the Events page of Moleculin's website and archived for 90 days.
Moleculin Biotech (Nasdaq: MBRX), un'azienda farmaceutica in fase avanzata focalizzata nello sviluppo di trattamenti per tumori e virus difficili da trattare, ha programmato l'annuncio dei risultati finanziari per l'intero anno 2024 per il 21 marzo 2025.
L'azienda ospiterà una conferenza telefonica e una diretta audio in streaming per discutere i risultati operativi e finanziari il 24 marzo 2025, alle 8:30 AM ET. Gli investitori possono partecipare telefonicamente componendo il numero (877) 407-0832 (nazionale) o (201) 689-8433 (internazionale). Il webcast sarà disponibile nella pagina Eventi del sito web di Moleculin e archiviato per 90 giorni.
Moleculin Biotech (Nasdaq: MBRX), una empresa farmacéutica en etapa avanzada centrada en el desarrollo de tratamientos para tumores y virus difíciles de tratar, ha programado el anuncio de sus resultados financieros del año completo 2024 para el 21 de marzo de 2025.
La empresa llevará a cabo una conferencia telefónica y una transmisión en vivo de audio para discutir los resultados operativos y financieros el 24 de marzo de 2025, a las 8:30 AM ET. Los inversores pueden unirse por teléfono marcando (877) 407-0832 (nacional) o (201) 689-8433 (internacional). La transmisión estará disponible en la página de Eventos del sitio web de Moleculin y se archivará durante 90 días.
몰레큘린 바이오텍 (Nasdaq: MBRX), 치료하기 어려운 종양과 바이러스 치료 개발에 집중하는 후기 단계 제약 회사가 2024년 전체 재무 결과 발표를 2025년 3월 21일로 예정했습니다.
회사는 2025년 3월 24일 오전 8시 30분 ET에 운영 및 재무 결과를 논의하기 위해 전화 회의와 라이브 오디오 웹캐스트를 개최할 예정입니다. 투자자는 (877) 407-0832 (국내) 또는 (201) 689-8433 (국제)로 전화하여 참여할 수 있습니다. 웹캐스트는 몰레큘린 웹사이트의 이벤트 페이지에서 이용 가능하며 90일 동안 아카이브됩니다.
Moleculin Biotech (Nasdaq: MBRX), une entreprise pharmaceutique en phase avancée axée sur le développement de traitements pour des tumeurs et des virus difficiles à traiter, a prévu l'annonce de ses résultats financiers pour l'année complète 2024 pour le 21 mars 2025.
L'entreprise organisera une conférence téléphonique et un webinaire audio en direct pour discuter des résultats opérationnels et financiers le 24 mars 2025 à 8h30 ET. Les investisseurs peuvent participer par téléphone en composant le (877) 407-0832 (national) ou le (201) 689-8433 (international). Le webinaire sera disponible sur la page Événements du site Web de Moleculin et sera archivé pendant 90 jours.
Moleculin Biotech (Nasdaq: MBRX), ein pharmazeutisches Unternehmen in der späten Entwicklungsphase, das sich auf die Entwicklung von Behandlungen für schwer zu behandelnde Tumoren und Viren konzentriert, hat die Bekanntgabe seiner finanziellen Ergebnisse für das gesamte Jahr 2024 auf den 21. März 2025 festgelegt.
Das Unternehmen wird am 24. März 2025 um 8:30 Uhr ET eine Telefonkonferenz und einen Live-Audio-Webcast abhalten, um die operativen und finanziellen Ergebnisse zu besprechen. Investoren können sich telefonisch unter (877) 407-0832 (national) oder (201) 689-8433 (international) einwählen. Der Webcast wird auf der Veranstaltungsseite der Moleculin-Website verfügbar sein und 90 Tage lang archiviert werden.
- None.
- None.
HOUSTON, March 19, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced that it will report its financial results for the year ended December 31, 2024, on Friday afternoon, March 21, 2025. Moleculin management will host a conference call and live audio webcast to discuss the operational and financial results on Monday morning, March 24, 2025 at 8:30 AM ET.
Interested participants and investors may access the conference call by dialing (877) 407-0832 (domestic) or (201) 689-8433 (international) and referencing the Moleculin Biotech Conference Call. The live audio webcast will be accessible on the Events page of the Investors section of the Moleculin website, moleculin.com, and will be archived for 90 days.
About Moleculin Biotech, Inc.
Moleculin Biotech, Inc. is a Phase 3 clinical stage pharmaceutical company advancing a pipeline of therapeutic candidates addressing hard-to-treat tumors and viruses. The Company’s lead program, Annamycin, is a next-generation anthracycline designed to avoid multidrug resistance mechanisms and to eliminate the cardiotoxicity common with currently prescribed anthracyclines. Annamycin is currently in development for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases.
The Company is initiating the MIRACLE (Moleculin R/R AML AnnAraC Clinical Evaluation) Trial (MB-108), a pivotal, adaptive design Phase 3 trial evaluating Annamycin in combination with cytarabine, together referred to as AnnAraC, for the treatment of relapsed or refractory acute myeloid leukemia. Following a successful Phase 1B/2 study (MB-106), with input from the FDA, the Company believes it has substantially de-risked the development pathway towards a potential approval for Annamycin for the treatment of AML. This study is subject to appropriate future filings with potential additional feedback from the FDA and their foreign equivalents.
Additionally, the Company is developing WP1066, an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while also stimulating a natural immune response, targeting brain tumors, pancreatic and other cancers. Moleculin is also engaged in the development of a portfolio of antimetabolites, including WP1122 for the potential treatment of pathogenic viruses, as well as certain cancer indications.
For more information about the Company, please visit www.moleculin.com and connect on X, LinkedIn and Facebook.
Investor Contact:
JTC Team, LLC
Jenene Thomas
(908) 824-0775
MBRX@jtcir.com
FAQ
When will Moleculin Biotech (MBRX) release its 2024 financial results?
How can investors join Moleculin's (MBRX) earnings conference call?
Where can I access the webcast of MBRX's 2024 earnings call?
What is the time gap between MBRX's 2024 results release and the earnings call?
